← Issue №18/ week of Nov 1, 2026/Hepatology

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=538 · Nov 1, 2026 · Liver International · IF 6.7

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.

New evidencehepatocellular carcinoma
Clinical takeawayConsider using ESC Cardio-Oncology classification or CARDIOSOR score to stratify cardiovascular risk in patients with uHCC before initiating atezolizumab/bevacizumab therapy. For high-risk patients, weigh bevacizumab-free alternatives as a comparator.
What it foundPatients classified as very high-risk by ESC Cardio-Oncology classification (specific thresholds not provided in abstract) or high-risk by CARDIOSOR score (specific thresholds not provided in abstract) had significantly increased risk of tMACE (3.7%) and eMACE (5.6%).
ContextThis study provides evidence for cardiovascular risk stratification in uHCC patients on atezolizumab/bevacizumab, addressing a gap in cirrhosis-specific risk assessment.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Stefanini B … ARTE Study Group · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues